Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Skip More from NICE submenu
Explore more from NICE
What NICE does
About us
Reusing our content
Implementing NICE guidance
News, blogs and podcasts
Contact us
Get involved
Careers
Join a committee
Comment on a consultation
Close menu
My account
Consultation responses
Sign in
You are here:
Home
NICE Guidance
Published Guidance
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Technology appraisal guidance
Reference number:
TA619
Published:
15 January 2020
This guidance has been updated and replaced by
NICE technology appraisal guidance 836
.
Back to top